COVID-19 vaccine could be ready late November, says Pfizer

*Company says it continues to believe in its vaccine candidate and expects to have the necessary data to win EUA from US Food and Drug Administration (FDA) by third week of November.

Emmanuel Akosile | ConsumerConnect

As the global community much awaits the production and distribution of vaccines against the ravaging Coronavirus (COVID-19) pandemic, leading drugmaker Pfizer has disclosed that its virus vaccine candidate could be ready to apply for emergency use authorisation (EUA) by the end of November, and make it available to consumers.

ConsumerConnect reports Dr. Albert Bourla, Chief Executive Officer (CEO) of Pfizer, in an open letter Friday, October 16, said he was commenting on a potential timeline for the company’s vaccine because he wanted to eliminate confusion about what he described as “a complex process”.

Bourla stated:

“To ensure public trust and clear up a great deal of confusion, I believe it is essential for the public to understand our estimated timelines.”

The compnay CEO’s statement comes as cases of the virus have begun to increase and health experts have warned that a “second wave” of illnesses could occur during the fall and winter.

The wave already appears to be hitting Europe, which has reported a sharp increase in cases, report said.

While Pfizer’s news strikes a hopeful tone, yet, it was learnt it is coming with a number of caveats.

Whereas it could seek permission to distribute the vaccine as soon as next month, everything would have to go right with its late stage human trials.

The company would also have to provide safety data and prove that the treatment can produce positive efficacy.

ConsumerConnect recently reported that Johnson & Johnson stopped the late stage trial for its vaccine candidate after one of the participants appeared to have an adverse reaction.

Pfizer, however, disclosed that the participant’s illness is “being reviewed and evaluated.”

The company had commented on the development that “adverse events ─ illnesses, accidents, etc.─ even those that are serious, are an expected part of any clinical study, especially large studies.”

Now, Pfizer which is working on a vaccine with another drug company, BioNTech SE, has revealed that it continues to believe in its candidate and expects to have the necessary data to win EUA from the U.S. Food and Drug Administration (FDA). Specifically, Pfizer said it believes it will have data showing the drug is safe by the third week of November.

But how about the reported hesitancy by the consumers? Assuming the trial results show the vaccine is safe for humans and is effective in preventing the Coronavirus, Pfizer said it would immediately file for EUA.

The drugmaker is also working on a report that would show how quickly the drug could be manufactured in large quantities and distributed to the public, according to report.

Several other pharmaceutical companies are currently working on a potential vaccine, but it’s not clear how widely any vaccine would be used, at least initially.

Earlier in the week, researchers at the Brigham Young University released a survey showing hesitancy on the part of the public to be first in line to get vaccinated.

Kindly Share This Story